Atlas Trials

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Clinical trial NCT07667335 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07667335
Sponsor
Fred Hutchinson Cancer Center
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Bladder Giant Cell Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaStage IIIB Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Unresectable Bladder Urothelial CarcinomaUnresectable Renal Pelvis Urothelial Carcinoma
Start date
2026-12-01
Primary completion
2029-07-16
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.